iScience (Feb 2024)

Helical peptides with disordered regions for measles viruses provide new generalized insights into fusion inhibitors

  • Kazushige Hirata,
  • Aoi Takahara,
  • Satoshi Suzuki,
  • Shumei Murakami,
  • Kumi Kawaji,
  • Akie Nishiyama,
  • Mina Sasano,
  • Mariko Shoji-Ueno,
  • Emiko Usui,
  • Kazutaka Murayama,
  • Hironori Hayashi,
  • Shinya Oishi,
  • Eiichi N. Kodama

Journal volume & issue
Vol. 27, no. 2
p. 108961

Abstract

Read online

Summary: Despite effective vaccines, measles virus (MeV) outbreaks occur sporadically. Therefore, developing anti-MeV agents remains important for suppressing MeV infections. We previously designed peptide-based MeV fusion inhibitors, M1 and M2, that target MeV class I fusion protein (F protein). Here, we developed a novel fusion inhibitor, MEK35, that exerts potent activity against M1/M2-resistant MeV variants. Comparing MEK35 to M1 derivatives revealed that combining disordered and helical elements was essential for overcoming M1/M2 resistance. Moreover, we propose a three-step antiviral process for peptide-based fusion inhibitors: (i) disordered peptides interact with F protein; (ii) the peptides adopt a partial helical conformation and bind to F protein through hydrophobic interactions; and (iii) subsequent interactions involving the disordered region of the peptides afford a peptide-F protein with a high-affinity peptide-F protein interaction. An M1-resistant substitution blocks the second step. These results should aid the development of novel viral fusion inhibitors targeting class I F protein.

Keywords